1. (Journal Article): Normalization of glucose concen-trations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA
 
ABSTRACT: The effects of different i.v. doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients w...

2. (Journal Article): Gastric inhibitory polypeptide: the neglected incretin revisited.

Meier JJ, Nauck MA, Schmidt WE, Gallwitz B
 
ABSTRACT: After the ingestion of fat- and glucose-rich meals, gut hormones are secreted into the circulation in order to stimulate insulin secretion. This so-called "incretin effect&quo...

3. (Journal Article): Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W
 
ABSTRACT: Integrated insulin secretion rates calculated from peripheral venous C-peptide measurements by two-compartment kinetic analysis were measured in six young normal subjects after inc...

4. (Journal Article): Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.

Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA
 
ABSTRACT: In patients with type 2 diabetes, gastric inhibitory polypeptide (GIP) has lost much of its insulinotropic activity. Whether this is similar in first-degree relatives of patients w...

5. (Journal Article): Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhi-bitory polypeptide in patients with type-2 diabetes mellitus.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W
 
ABSTRACT: In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibit...

6. (Journal Article): Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W
 
ABSTRACT: Glucagon-like peptide 1 (GLP-1) (7-36 amide) is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates insulin secretion at eleva...

7. (Journal Article): The potential role of glucagon-like peptide 1 in diabetes.

Meier JJ, Nauck MA
 
ABSTRACT: The incretin hormone glucagon-like peptide 1 (GLP-1) has a promising potential for the treatment of type 2 diabetes due to its glucose-dependent insulinotropic and glucagonostatic ...

8. (Journal Article): Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W
 
ABSTRACT: Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respect...

9. (Journal Article): Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.

Meier JJ, Gallwitz B, Nauck MA
 
ABSTRACT: Although the insulinotropic actions of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been known for almost 2 decades, the incretin hormones have not...

10. (Journal Article): Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.

Meier JJ, Gallwitz B, Schmidt WE, Nauck MA
 
ABSTRACT: After ingestion of carbohydrate- and fat-rich meals, the incretin hormone glucagon-like peptide 1 (GLP-1) is secreted from the L-cells in the distal put into the circulation. Its m...